Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.43 |
| ▸ | HRH2 | P25021 | 3/20 | 0.43 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295718 | 1.00 | PDCD1 (0.45) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL1360023 | 1.00 | PDCD1 (0.45) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL28960041 | 0.89 | PDCD1 (0.49) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL2116341 | 0.88 | HTR1A (0.49) | PDCD1CD274HRH3HRH2HRH1 | |
| SCHEMBL9912480 | 0.86 | — | — | |
| SCHEMBL1099390 | 0.86 | KCNA3 (0.43) | HRH3HRH2HRH1KCNA3 | |
| SCHEMBL9912445 | 0.86 | — | — | |
| SCHEMBL1361943 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL27790308 | 0.84 | KCNA3 (0.42) | HRH3HRH2HRH1KCNA3 | |
| SCHEMBL28960037 | 0.84 | PDCD1 (0.44) | PDCD1CD274HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463506-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF AURORA KINASES | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | PDCD1 1816/4885CD274 3516/4885HRH3 1050/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | PDCD1 2025/4885CD274 3979/4885HRH3 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.